Navigation Links
IDO2 an active enzyme to target in pancreatic cancer
Date:12/1/2008

nt in order to have an active IDO2 enzyme.

Nineteen percent of the patients were homozygous wild-type, meaning they had two active alleles, and 42 percent of the patients were heterozygous, meaning they had one active allele. Twenty-five percent were homozygous for two inactive IDO2 alleles. The remaining 14 percent were difficult to determine due to limits in sequencing and distinguishing the alleles, but were most likely heterozygous, according to Dr. Brody.

Phase-1 studies of 1-MT, the IDO inhibitor are currently underway.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
2. USA-ONE Interactive Announces Document Management Solutions That Meet the Needs of Individual Industries
3. TeleHealth Services TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center
4. Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein
5. Boomers Play an Active Role with Parent's Medication Decisions
6. Active Young Women Need Calcium, Vitamin D
7. The HealthCentral Networks MyDiabetesCentral.com Launches Interactive Resource to Promote Awareness of Diabetes
8. iTech Fitness Taps Metzger for National Active Gaming Campaign
9. Virgin Active Says Leave the Cleavage to the Girls
10. LodgeNet Interactive to Report Third Quarter Results on October 28th
11. MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 1The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 2The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 4Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 1Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 2Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 3Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 4Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 1Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 2Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 3Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 4
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12